CORRECT: Avacta reports progress in faridoxorubicin clinical programme
(Correcting that Avacta Group is headquartered in London). Read More
| Price | 60.50p on 06-02-2026 at 18:50:05 |
|---|---|
| Change | 0.50p 0.83% |
| Buy | 62.00p |
| Sell | 59.00p |
| Last Trade: | Unknown 1,905.00 at 60.50p |
| Day's Volume: | 742,879 |
| Last Close: | 60.50p |
| Open: | 60.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 60.50p - 60.90p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £264.77m |
| VWAP: | 60.25258p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 1,905 | 60.50p | OTC Trade |
17:09:28 - 06-Feb-26 |
| Sell* | 9,158 | 59.75p | Ordinary |
16:37:38 - 06-Feb-26 |
| Buy* | 11,516 | 60.78p | Ordinary |
16:28:46 - 06-Feb-26 |
| Sell* | 20,000 | 60.02p | Ordinary |
16:27:48 - 06-Feb-26 |
| Buy* | 31 | 61.149p | Ordinary |
16:25:40 - 06-Feb-26 |
| Sell* | 799 | 59.00p | Ordinary |
16:22:52 - 06-Feb-26 |
| Buy* | 3,800 | 60.78p | Ordinary |
16:19:59 - 06-Feb-26 |
| Buy* | 16,433 | 60.85p | Ordinary |
16:16:54 - 06-Feb-26 |
| Sell* | 48,000 | 59.9555p | Ordinary |
16:16:23 - 06-Feb-26 |
| Sell* | 5,000 | 59.9555p | Ordinary |
16:16:03 - 06-Feb-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |